Close
  Indian J Med Microbiol
 

Figure 1: Site of action of various antiplatelet drugs: Platelet activation inhibitors include (i) TXA2 pathway inhibitors which block either synthesis or receptors of TXA2, (ii) ADP receptor (P2Y12) inhibitors and (iii) thrombin receptor (PAR-1) inhibitors. Adhesion antagonists block interaction of collagen and vWF with GpVI and α2β1 receptors on platelets. GpIIb/IIIa inhibitors block binding of fi brinogen to their receptors on platelets. ADP, Adenosine di-phosphate; PAR-1, Protease-Activated Receptor-1; TP, Thromboxane receptor; TXA2, Thromboxane A2; vWF, Von Willebrand Factor

Figure 1: Site of action of various antiplatelet drugs: Platelet activation inhibitors include (i) TXA2 pathway inhibitors which block either synthesis or receptors of TXA<sub>2</sub>, (ii) ADP receptor (P<sub>2</sub>Y<sub>12</sub>) inhibitors and (iii) thrombin receptor (PAR-1) inhibitors. Adhesion antagonists block interaction of collagen and vWF with GpVI and α<sub>2</sub>β<sub>1</sub> receptors on platelets. GpIIb/IIIa inhibitors block binding of fi brinogen to their receptors on platelets. ADP, Adenosine di-phosphate; PAR-1, Protease-Activated Receptor-1; TP, Thromboxane receptor; TXA<sub>2</sub>, Thromboxane A<sub>2</sub>; vWF, Von Willebrand Factor